35 results on '"Rosenblat, Joshua D"'
Search Results
2. Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine
3. Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis
4. Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis
5. Comparing suicide completion rates in bipolar I versus bipolar II disorder: A systematic review and meta-analysis
6. Impact of vortioxetine on depressive symptoms moderated by symptoms of anxiety in persons with post-COVID-19 condition: A secondary analysis
7. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS)
8. Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review
9. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
10. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis
11. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review
12. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review
13. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin
14. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data
15. Association of SARS-CoV-2 infection with neurological impairments in pediatric population: A systematic review
16. Association between fatigue and depressive symptoms in persons with post-COVID-19 condition: a post hoc analysis
17. Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the united states food and drug administration adverse event reporting system (FAERS)
18. Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system
19. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes
20. Impact of Elevated Body Mass Index (BMI) on Cognitive Functioning and Inflammation in Persons with Post-COVID-19 Condition: A Secondary Analysis
21. Adjunctive cariprazine for major depressive disorder: a systematic review and meta-analysis
22. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
23. Prescribed psychostimulants and other pro‐cognitive medications in bipolar disorder: A systematic review and meta‐analysis of recurrence of manic symptoms.
24. The Impact of Cognitive Function on Health-Related Quality of Life in Persons with Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine
25. Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression
26. Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine
27. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis
28. Corrigendum to “COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis” [Brain Behav. Immun. 111 (2023) 211–229]
29. Association between Cognitive Functioning, Suicidal Ideation and Suicide Attempts in Major Depressive Disorder, Bipolar Disorder, Schizophrenia and Related Disorders: A Systematic Review and Meta-Analysis
30. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial.
31. Psychotropic Drug–Related Weight Gain and Its Treatment.
32. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)
33. Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.
34. The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS).
35. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.